Evaluation of Resource Utilization and Treatment Patterns in Patients with Actinic Keratosis in the United States

被引:8
|
作者
Asche, Carl V. [1 ,2 ,3 ]
Zografos, Panagiotis [4 ]
Norlin, Jenny M. [5 ]
Urbanek, Bill [4 ]
Mamay, Carl [4 ,6 ]
Makin, Charles
Erntoft, Sandra [5 ]
Chen, Chi-Chang [6 ]
Hines, Dionne M. [6 ]
Siegel, Daniel Mark [7 ,8 ]
机构
[1] Univ Illinois, Coll Med, Ctr Outcomes Res, One Illini Dr, Peoria, IL 61656 USA
[2] Univ Illinois, Coll Med, Dept Med, Peoria, IL 61656 USA
[3] Univ Illinois, Coll Pharm, Dept Pharm Syst Outcomes & Policy, Chicago, IL USA
[4] LEO Pharma Inc, Parsippany, NJ USA
[5] LEO Pharma A S, Ballerup, Denmark
[6] IMS Hlth, RWE HEOR Plymouth Meeting, Philadelphia, PA USA
[7] Suny Downstate, Dept Dermatol, Brooklyn, NY USA
[8] Long Isl Skin Canc Dermatol Surg, Smithtown, NY USA
关键词
actinic keratosis; health care resource utilization; treatment patterns; PHOTODYNAMIC THERAPY; FIELD CANCERIZATION; ECONOMIC-EVALUATION; SOLAR KERATOSES; CELL CARCINOMA; POPULATION; RISK; EPIDEMIOLOGY; NETHERLANDS; PREVALENCE;
D O I
10.1016/j.jval.2015.11.014
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objective: To compare health care resource utilization and treatment patterns between patients with actinic keratosis (AK) treated with ingenol mebutate gel (IngMeb) and those treated with other field directed AK therapies. Methods: A retrospective, propensity-score matched, cohort study compared refill/repeat and adding-on/switching patterns and outpatient visits and prescriptions (health care resource utilization) over 6 months in patients receiving IngMeb versus those receiving imiquimod, 5-fluorouracil, diclofenac sodium, and methyl aminolevulinate or aminolevulinic acid photodynamic therapy (MAL/ALA-PDT). Results: The final sample analyzed included four matched treatment cohort pairs (IngMeb and comparator; n = 790-971 per treatment arm). Refill rates were similar except for imiquimod (15% vs. 9% for imiquimod and IngMeb, respectively; P < 0.05). MAL/ALA-PDT treatment repetition rates were higher than IngMeb refill rates (20% vs. 10%; P < 0.05). Topical agent add-on/switch rates were comparable. PDT had higher switch rates than did IngMeb (5% vs. 2%; P < 0.05). The IngMeb cohort had a significantly lower proportion of patients with at least one AK-related outpatient visit during the 6-month follow-up than did any other cohort: versus imiquimod (50% vs. 66%; P < 0.0001), versus 5-fluorouracil (50% vs. 69%; P < 0.0001), versus diclofenac sodium (51% vs. 56%; P = 0.034), and versus MAL/ALA-PDT (50% vs. 100%; P < 0.0001). There were significantly fewer AK-related prescriptions among patients receiving IngMeb than among patients in other cohorts. Conclusions: Results based on the first 6 months after treatment initiation suggested that most field-directed AK therapies had clinically comparable treatment patterns except imiquimod, which was associated with higher refill rates, and PDT, which was associated with significantly more frequent treatment sessions and higher switching rates. IngMeb was also associated with significantly fewer outpatient visits than were other field-directed therapies.
引用
收藏
页码:239 / 248
页数:10
相关论文
共 50 条
  • [21] Pharmacokinetic and pharmacodynamic evaluation of ingenol mebutate for the treatment of actinic keratosis
    Stockfleth, Eggert
    Bastian, Mike
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2018, 14 (09) : 911 - 918
  • [22] Treatment Patterns and Health Care Resource Utilization of Iatrogenic Spinal Cerebrospinal Fluid Leaks in the United States
    Charalambous, Lefko T.
    Rajkumar, Shashank
    Liu, Beiyu
    Adil, Syed M.
    Wong, Megan
    Hodges, Sarah
    Amrhein, Timothy J.
    Leithe, Linda Gray
    Parente, Beth
    Lee, Hui-Jie
    Lad, Shivanand P.
    CLINICAL SPINE SURGERY, 2022, 35 (09): : E725 - E730
  • [23] Resource utilization among neuroendocrine tumor patients in the United States
    Casciano, Roman
    Chulikavit, Maruit
    Parikh, Rohan
    Stern, Lee
    Liu, Zhimei
    Wang, Xufang
    Strosberg, Jonathan R.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [24] Healthcare resource utilization among haemophilia A patients in the United States
    Valentino, L. A.
    Pipe, S. W.
    Tarantino, M. D.
    Ye, X.
    Xiong, Y.
    Luo, M. P.
    HAEMOPHILIA, 2012, 18 (03) : 332 - 338
  • [25] Resource utilization among neuroendocrine tumor patients in the United States
    Casciano, Roman
    Chulikavit, Maruit
    Parikh, Rohan
    Stern, Lee
    Liu, Zhimei
    Wang, Xufang
    Grzegorzewski, Kris
    Strosberg, Jonathan R.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [26] ASSESSMENT OF IMAGING UTILIZATION AND TREATMENT PATTERNS FOR HEAD AND NECK CANCER PATIENTS IN THE UNITED STATES
    Bresnahan, B. W.
    Alfonso-Cristancho, R.
    He, H.
    Mendez, E.
    Goulart, B.
    Parvathaneni, U.
    Kramer, B.
    Anzai, Y.
    VALUE IN HEALTH, 2014, 17 (03) : A98 - A98
  • [27] Characterizing Treatment Utilization Patterns for Trigeminal Neuralgia in the United States
    Zakrzewska, Joanna M.
    Wu, Ning
    Lee, John Y. K.
    Werneburg, Brian
    Hoffman, Deborah
    Liu, Ying
    CLINICAL JOURNAL OF PAIN, 2018, 34 (08): : 691 - 699
  • [28] GLIOBLASTOMA TREATMENT PATTERNS AND OUTCOMES AND RESOURCE USE IN THE UNITED STATES
    Girvan, Allicia
    Carter, Gebra
    Li, Li
    Kaltenboeck, Anna
    Chawla, Anita
    Ivanova, Jasmina
    Koh, Maria
    Stevens, Jessi
    Lahn, Michael
    NEURO-ONCOLOGY, 2013, 15 : 110 - 110
  • [29] TRENDS IN DIAGNOSTIC PREVALENCE, TREATMENT PATTERNS, AND HEALTHCARE RESOURCE UTILIZATION OF ADULT PATIENTS WITH FOOD ALLERGIES IN THE UNITED STATES, 2008-2018
    Hunter, T.
    Nowak, C.
    Shan, M.
    Hoyt, M.
    Choong, C.
    Mills, K.
    VALUE IN HEALTH, 2021, 24 : S216 - S216
  • [30] TREATMENT PATTERNS, HEALTHCARE RESOURCE UTILIZATION AND ASSOCIATED COSTS BY LINE OF THERAPY IN NEWLY DIAGNOSED MERKEL CELL CANCER PATIENTS IN THE UNITED STATES
    Kearney, M.
    Boutmy, E.
    Locker, M.
    Penalvo, J.
    Bharmal, M.
    VALUE IN HEALTH, 2018, 21 : S46 - S46